CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Letrozoledrug
Likely dose
Letrozole 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02389088
NCT02389088N/ACompleted
CompareCT.gov

Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH

University of California, San Diego·interventional·Posted Mar 17, 2015·Updated Mar 10, 2016

In Brief

A clinical study evaluating Letrozole for Polycystic Ovary Syndrome. Completed, enrolled 9 participants.

Detailed Summary

The purpose of this study is to evaluate the effect of increased circulating androgens on estradiol production by the granulosa cells in response to FSH stimulus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Ovary Syndrome
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 17, 2015
Enrollment StartApr 1, 2006
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 11.3 years ago

Interventions

Letrozoledrug

In Phase II, letrozole, 5 mg/day, will be given for 14 days